首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1392014

皮膚癌治療市場：依藥物類型、癌症類型、給藥途徑、配銷通路、地區

Skin Cancer Drugs Market, By Drug Type, By Cancer Type, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2023年11月10日 | 出版商:

Coherent Market Insights | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球皮膚癌藥物市場規模預計將從 2023 年的 87.8 億美元增至 2030 年的 153.2 億美元，預測期內複合年成長率為 8.3%。

報告範圍		報告詳情
基準年	2022年	2023年市場規模	87.8億美元
實績資料	2018-2021	預測期	2023-2030
預測期複合年成長率	8.30%	2030年市場規模預測	153.2億美元

圖 1. 2023 年依地區分類的皮膚癌藥物全球市場佔有率(%)

皮膚癌是一種影響皮膚細胞的癌症，是由暴露於紫外線 (UV) 輻射（主要來自陽光或日光浴床）引起的。它是全世界最常見的癌症之一，其發生率逐年上升。為了應對這一日益成長的趨勢，製藥公司正在專注於皮膚癌治療的開發和創新。

市場動態：

皮膚癌治療市場主要是由全球皮膚癌發生率上升所推動的。過度暴露於紫外線、生活方式的改變和高齡化等因素導致這種疾病的盛行率不斷上升。此外，治療性介入的進步和標靶治療的引入進一步推動了市場的成長。

市場相關人員正在努力獲得皮膚癌藥物的監管核准，預計這將在預測期內促進全球皮膚癌藥物市場的成長。例如，2021年1月，總部位於印度的跨國製藥公司Sun Pharma推出了一種「發光二極體」LED光源，用於臉部或頭皮的輕度至中度厚度的動態治療（PDT）。聯合Levulan Kerastick （氨基乙醯丙酸）鹽酸）已獲得美國食品藥物管理局（美國 FDA）核准。這為患者提供了一種侵入性較小的治療方法。

然而，也存在一些阻礙市場成長的課題。高昂的藥物開發成本和嚴格的監管要求是新參與企業的主要障礙。與某些藥物相關的副作用和替代治療方案的可用性是市場成長的抑制因素。

儘管存在這些課題，市場仍存在一些成長機會。增加對研發（R＆D）活動的投資以及製藥公司和研究機構之間的合作預計將推動創新和新治療方案的推出。此外，對個人化醫療和聯合治療的使用的日益關注提供了市場擴張潛力。

本研究的主要特點

該報告對全球皮膚癌治療市場進行了詳細分析，並提供了以2022年為基準年的預測期（2023-2030）的市場規模和年複合成長率（CAGR%）。
該報告還揭示了各個區隔市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
該報告還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
該報告根據公司亮點、產品系列、主要亮點、財務實績和策略等參數，介紹了全球皮膚癌治療市場的主要企業。
該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的資訊。
全球皮膚癌治療藥物市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
相關人員可以透過用於分析全球皮膚癌治療藥物市場的各種策略矩陣來促進他們的決策。

介紹
北美洲
美國
加拿大
拉丁美洲
巴西
阿根廷
墨西哥
其他拉丁美洲
歐洲
德國
英國
西班牙
法國
義大利
俄羅斯
歐洲其他地區
亞太地區
中國
印度
日本
澳洲
韓國
東南亞國協
其他亞太地區
中東
海灣合作理事會國家
以色列
其他中東地區
非洲
南非
北非
中部非洲

第10章競爭形勢

公司簡介
Novartis
Merck
Roche
Amgen
Pfizer
Sun Pharma
Bristol-Myers Squibb
AstraZeneca
Johnson & Johnson
Valeant
Daiichi Sankyo
Takeda Pharmaceutical
LEO Pharma
Mylan NV
Sanofi
Regeneron
Eli Lilly
Bayer
Gilead Sciences
Astellas Pharma

第11章章節

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI6345

Global skin cancer drugs market size is expected to reach US$ 15.32 Bn by 2030, from US$ 8.78 Bn in 2023, at a CAGR of 8.3% during the forecast period.

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 8.78 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	8.30%	2030 Value Projection:	US$ 15.32 Bn

Figure 1. Global Skin Cancer Drugs Market Share (%), By Region, 2023

Skin cancer is a type of cancer that affects the skin cells and is primarily caused by exposure to ultraviolet (UV) radiation from the sun or tanning beds. It is one of the most prevalent cancers globally, and its incidence has been increasing over the years. To combat this rising trend, pharmaceutical companies have been focusing on the development and innovation of skin cancer drugs.

Market Dynamics:

The skin cancer drugs market is primarily driven by the rising incidence of skin cancer worldwide. Factors such as excessive exposure to UV radiation, changing lifestyles, and an aging population contribute to the increasing prevalence of the disease. Moreover, advancements in therapeutic interventions and the introduction of targeted therapies have further fueled the market growth.

Market players are engaged in receiving approval from the regulatory authorities for the skin cancer drugs and this is expected to increase the growth of the global skin cancer drugs market, over the forecast period. For instance, in January 2021, Sun Pharma, a India based multinational pharmaceutical company, gained U.S. Food and Drug Administration (U.S. FDA) approval for Levulan Kerastick (aminolevulinic acid HCl) in combination with its "Light Emitting Diode" LED light source for photodynamic therapy (PDT) of minimally to moderately thick actinic keratosis of the face or scalp. It offers patients a less invasive treatment option.

However, there are several challenges that hinder the market growth. High drug development costs and stringent regulatory requirements pose significant barriers for new entrants. Adverse side effects associated with certain drugs and the availability of alternative treatment options act as restraining factors for market growth.

Despite these challenges, the market presents several opportunities for growth. Increasing investments in research and development (R&D) activities, along with collaborations between pharmaceutical companies and research institutions, are expected to drive innovation and the introduction of novel treatment options. Moreover, the growing focus on personalized medicine and the use of combination therapies offer potential avenues for market expansion.

Key features of the study:

This report provides in-depth analysis of the global skin cancer drugs market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global skin cancer drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novartis, Merck, Roche, Amgen, Pfizer, Sun Pharma, Bristol-Myers Squibb, AstraZeneca, Johnson & Johnson, Valeant, Daiichi Sankyo, Takeda Pharmaceutical, LEO Pharma, Mylan N.V., Sanofi, Regeneron, Eli Lilly, Bayer, Gilead Sciences and Astellas Pharma
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global skin cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global skin cancer drugs market

Detailed Segmentation:

By Drug Type
- Chemotherapy Drugs
- Targeted Therapy Drugs
- Immunotherapy Drugs
- Hormone Therapy Drugs
- Others (Photodynamic Therapy, Cryotherapy and Others)
By Cancer Type
- Basal cell carcinoma
- Squamous cell carcinoma
- Melanoma
- Others (Kaposi's sarcoma, Mycosis fungoides and Others)
By Route of Administration
- Topical
- Oral
- Injectable
- Others (Surgical procedures, radiation therapy and Others)
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Top Companies in Global Skin Cancer Drugs Market:
- Novartis
- Merck
- Roche
- Amgen
- Pfizer
- Sun Pharma
- Bristol-Myers Squibb
- AstraZeneca
- Johnson & Johnson
- Valeant
- Daiichi Sankyo
- Takeda Pharmaceutical
- LEO Pharma
- Mylan N.V.
- Sanofi
- Regeneron
- Eli Lilly
- Bayer
- Gilead Sciences
- Astellas Pharma

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Cancer Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increasing incidence of skin cancers
- High costs of targeted therapies
- Combination therapies
Key Highlights
Regulatory Scenario
Recent Trends
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Mergers, Acquisitions, and Collaborations

4. Global Skin Cancer Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Skin Cancer Drugs Market, By Drug Type, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Chemotherapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Targeted Therapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Immunotherapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Hormone Therapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Others (Photodynamic Therapy, Cryotherapy and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

6. Global Skin Cancer Drugs Market, By Cancer Type, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Basal cell carcinoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Squamous cell carcinoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Melanoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Others (Kaposi's sarcoma, Mycosis fungoides and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

7. Global Skin Cancer Drugs Market, By Route of Administration, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Others (Surgical procedures, radiation therapy and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

8. Global Skin Cancer Drugs Market, By Distribution Channel, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

9. Global Skin Cancer Drugs Market, By Region, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, By Sub-region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Sub-region, 2019 -2030
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2018-2030,(US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2018-2030,(US$ Bn)
South Africa
North Africa
Central Africa

10. Competitive Landscape

Company Profile
Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck
Roche
Amgen
Pfizer
Sun Pharma
Bristol-Myers Squibb
AstraZeneca
Johnson & Johnson
Valeant
Daiichi Sankyo
Takeda Pharmaceutical
LEO Pharma
Mylan N.V.
Sanofi
Regeneron
Eli Lilly
Bayer
Gilead Sciences
Astellas Pharma
Analyst Views